



NDA 209606/S-007

**SUPPLEMENT APPROVAL  
FULFILLMENT OF POSTMARKETING  
REQUIREMENT**

Bristol-Myers Squibb Company  
Attention: Sohrab Sadeghi, PharmD  
Senior Manager, Global Regulatory Strategy  
1000 Sierra Point Parkway  
Brisbane, CA 94005

Dear Dr. Sadeghi:

Please refer to your supplemental new drug application (sNDA) dated August 19, 2024, received August 19, 2024, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for IDHIFA (enasidenib) tablets.

This Prior Approval sNDA provides for updates to the United States Prescribing Information (USPI) in Section 12.3 Pharmacokinetics based upon data from Study CC--90007-CP-007.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your supplemental application, you are exempt from this requirement.

### **FULFILLMENT OF POSTMARKETING REQUIREMENT**

We have received your submission dated October 30, 2023, containing the final report for the following postmarketing requirement listed in the August 1, 2017, approval letter.

- 3240-5 Conduct a clinical pharmacokinetic trial to determine an appropriate dose of enasidenib in patients with hepatic impairment. This trial should be designed and conducted in accordance with the FDA Guidance for Industry entitled "*Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling*."

We have reviewed your submission and conclude that the above requirement was fulfilled.

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

We remind you that there is a postmarketing requirement listed in the August 1, 2017, approval letter that is still open.

### **PATENT LISTING REQUIREMENTS**

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Saumya Nathan, Senior Regulatory Project Manager, at 301-348-1963 or via e-mail to [Saumya.Nathan@fda.hhs.gov](mailto:Saumya.Nathan@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Kelly Norsworthy, MD  
Deputy Division Director  
Division of Hematologic Malignancies I  
Office of Oncologic Diseases  
Center for Drug Evaluation and Research

### **ENCLOSURE(S):**

- Content of Labeling
  - Prescribing Information
  - Medication Guide

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

KELLY J NORSWORTHY  
01/16/2025 04:12:36 PM